Hypoattenuating leaflet thickening was detected in 21.3% of patients 30 days after SAPIEN 3 Ultra RESILIA implantation, and was independently associated with hourglass-shaped frame and asymmetricity.
Cohort (n=445)
What is the incidence, predictors, and clinical impact of hypoattenuating leaflet thickening 30 days after SAPIEN 3 Ultra RESILIA implantation?
The SAPIEN 3 Ultra RESILIA valve has a 21.3% incidence of HALT at 30 days, which is associated with frame deformation and higher mean aortic gradients.
BACKGROUND: The latest-generation SAPIEN 3 Ultra RESILIA (S3UR) transcatheter heart valve (THV) incorporates several changes in leaflet design, including an improved anticalcification coating and modified commissural attachment. There are no established data on hypoattenuating leaflet thickening (HALT) following transcatheter aortic valve implantation (TAVI) using the S3UR. AIMS: Our study aimed to elucidate the clinical features of HALT following S3UR implantation. METHODS: As a subset of the OCEAN (Optimized CathEter vAlvular INtervention)-TAVI registry, we prospectively assessed patients who underwent cardiac computed tomography (CT) 30 days after S3UR implantation. HALT and potentially relevant THV geometry were analysed using four-dimensional CT data by an independent core laboratory. RESULTS: Of the 445 patients studied, HALT was detected in 95 patients (21.3%) 30 days after TAVI. The modification of the commissural attachment specific to the 20 mm and 23 mm S3UR THVs did not affect the incidence of HALT (22.1% for ≤23 mm; 20.2% for ≥26 mm; p=0.636). The hourglass-shaped THV frame (p25% vs HALT ≤25%: 10.3 interquartile range [IQR 7.0-13.0] mmHg vs 8.6 IQR 6.3-11.6 mmHg; p=0.007; HALT >50% vs HALT ≤50%: 11.5 IQR 7.0-14.3 mmHg vs 8.9 IQR 6.3-11.9 mmHg; p=0.002) was noted. CONCLUSIONS: The incidence of HALT for the S3UR was comparable with the already reported incidences for the previous-generation SAPIEN 3 THV. Given the haemodynamic impact of HALT severity and multiplicity, strategic planning to avoid deformation of the implanted THV might be required. (Clinical trial registration: UMIN000020423).
Ishizu et al. (Sat,) conducted a cohort in Transcatheter aortic valve implantation (TAVI) (n=445). SAPIEN 3 Ultra RESILIA (S3UR) implantation was evaluated on Hypoattenuating leaflet thickening (HALT) at 30 days. Hypoattenuating leaflet thickening was detected in 21.3% of patients 30 days after SAPIEN 3 Ultra RESILIA implantation, and was independently associated with hourglass-shaped frame and asymmetricity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: